## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no access to full text, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors report a structure-based virtual screening workflow combining molecular docking, molecular dynamics simulations, and binding free energy calculations to identify hit compounds targeting a druggable pocket on the DNA-binding domain (DBD) of human estrogen receptor alpha (ERalpha). They state that a lead core structure was synthesized and shown to inhibit E2-induced proliferation in MCF-7 cells, and propose this core as a basis for further antiestrogen drug optimization.
- **Visible evidence base** Abstract text only; no methodological details, numerical results, structural data, or experimental protocols are provided
- **Missing materials affecting confidence** Full manuscript, all figures and tables, computational parameters, docking scores, simulation details, binding free energy values, compound structures, synthesis procedures, and experimental assay data

## Reviewer
- **Overall assessment** The abstract presents a plausible and potentially useful computational-experimental strategy for targeting an alternative site on ERalpha, motivated by resistance mechanisms associated with LBD mutations. However, the evidence base available for this review is limited to the abstract, which lacks quantitative results, validation details, and sufficient methodological transparency. The central claims regarding pocket identification, hit discovery, and biological activity cannot be adequately assessed from the supplied material. The work may be of interest to the steroid hormone receptor and drug discovery communities, but the case is not established from the abstract alone.
- **Who would be interested in the results, and why** Researchers in breast cancer drug discovery, structural biology of nuclear receptors, and computational chemistry would be interested. The proposed alternative targeting of the DBD could offer a strategy to circumvent LBD-related resistance, which is a clinically relevant problem. The combined virtual screening and experimental validation approach may also appeal to those developing structure-based workflows for other transcription factors.
- **Major strengths** The rationale for targeting the DBD is clinically motivated and addresses a recognized limitation of current antiestrogen therapies. The integration of multiple computational methods with a synthetic and cell-based experimental component is a commendable workflow. The identification of a specific druggable pocket on the DBD provides a concrete hypothesis for further investigation.
- **Major Concerns**  
  - **Concern ID** R1-M1  
    **Severity** Major  
    **Blocking** Yes  
    **Axis** Evidence sufficiency  
    **Claim pointer** The authors claim that a druggable pocket on the DBD was identified as the potential binding site and that hits were found via virtual screening.  
    **Evidence pointer** Abstract; location not provided  
    **Concern** The abstract provides no quantitative or qualitative evidence for the pocket identification, such as pocket volume, residue composition, or comparison with known binding sites. No docking scores, enrichment factors, or hit selection criteria are reported.  
    **Why it matters** Without these details, the validity of the pocket as a druggable target and the reliability of the virtual screening results cannot be evaluated. The claim of a "druggable pocket" requires structural and computational support.  
    **Resolution test** Provide full methodological details and results, including pocket characterization, docking validation, and hit ranking metrics, in the manuscript.  
  - **Concern ID** R1-M2  
    **Severity** Major  
    **Blocking** Yes  
    **Axis** Experimental validation  
    **Claim pointer** The authors state that the core structure of the lead molecules was synthesized and found to inhibit E2-induced cell proliferation in MCF-7 cell lines.  
    **Evidence pointer** Abstract; location not provided  
    **Concern** No experimental details are given, including compound identity, concentration range, potency values, or statistical significance. The abstract does not specify whether the inhibition is dose-dependent or whether cytotoxicity was excluded.  
    **Why it matters** The biological claim is central to the translational relevance of the study. Without quantitative data and appropriate controls, the reported inhibition cannot be distinguished from nonspecific effects or assay artifacts.  
    **Resolution test** Report IC50 or comparable potency values, dose-response curves, cell viability controls, and statistical analysis in the full manuscript.  
  - **Concern ID** R1-M3  
    **Severity** Major  
    **Blocking** Yes  
    **Axis** Mechanistic link  
    **Claim pointer** The authors imply that the synthesized core structure acts by binding to the DBD and interfering with ERalpha-DNA recognition.  
    **Evidence pointer** Abstract; location not provided  
    **Concern** The abstract does not provide direct evidence that the observed antiproliferative effect is mediated by DBD binding. No data on DNA binding inhibition, cellular target engagement, or specificity for ERalpha over other nuclear receptors are presented.  
    **Why it matters** The proposed mechanism is the basis for the study's novelty and potential utility. Without evidence linking the compound's activity to DBD binding, the conclusions are speculative.  
    **Resolution test** Include assays such as electrophoretic mobility shift assays, reporter gene assays, or cellular thermal shift assays to demonstrate target engagement and mechanism.  
- **Minor Comments**  
  - **Concern ID** R1-m1  
    **Severity** Minor  
    **Axis** Clarity  
    **Affected element** Workflow description  
    **Evidence pointer** Abstract; location not provided  
    **Issue** The abstract states that molecular docking, molecular dynamics simulations, and binding free energy calculations were combined, but the order and integration of these steps are unclear.  
    **Required correction** Clarify the sequential or parallel use of these methods in the workflow description.  
  - **Concern ID** R1-m2  
    **Severity** Minor  
    **Axis** Terminology  
    **Affected element** "Druggable pocket"  
    **Evidence pointer** Abstract; location not provided  
    **Issue** The term "druggable" implies a level of validation that is not demonstrated in the abstract.  
    **Required correction** Use more neutral language such as "putative binding pocket" unless druggability is explicitly assessed.  
  - **Concern ID** R1-m3  
    **Severity** Minor  
    **Axis** Generalizability  
    **Affected element** Cell line choice  
    **Evidence pointer** Abstract; location not provided  
    **Issue** The use of MCF-7 cells is appropriate, but the abstract does not mention whether other ERalpha-positive or ERalpha-negative cell lines were tested for specificity.  
    **Required correction** State whether specificity was assessed and, if not, acknowledge this as a limitation.  
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3. The abstract lacks sufficient quantitative and methodological detail to support the central claims of pocket identification, biological activity, and mechanistic linkage.
- **Assessment against Nature-style criteria**  
  - Originality: The concept of targeting the DBD of ERalpha is not entirely novel but is a reasonable extension of existing efforts to find alternative binding sites. The specific combination of methods and the reported hit may offer some originality, but this cannot be fully assessed from the abstract.  
  - Scientific importance: The clinical motivation is strong, given resistance to LBD-targeting drugs. However, the importance of the findings depends on the robustness of the computational and experimental evidence, which is not visible here.  
  - Interdisciplinary readership: The work bridges computational chemistry, structural biology, and cancer biology, which could attract a broad audience. The abstract is written in a way that is accessible to nonspecialists, though technical details are lacking.  
  - Technical soundness: Cannot be evaluated from the abstract. The absence of methodological detail and quantitative results prevents assessment of the technical rigor.  
  - Readability for nonspecialists: The abstract is clear and concise, with minimal jargon, making it accessible. However, the lack of specific results limits its informative value.  
- **Recommendation posture** Currently not established from the provided evidence. The abstract presents a promising direction, but the absence of quantitative data and methodological transparency means the claims cannot be verified. A supportive posture would require access to the full manuscript and satisfactory resolution of the major concerns.

## Risk / unsupported claims
- The claim of a "druggable pocket" on the DBD is unsupported without structural and computational validation data.
- The claim that the synthesized core structure inhibits E2-induced proliferation is unsupported without dose-response data, controls, and statistical analysis.
- The implied mechanism of action via DBD binding and interference with ERalpha-DNA recognition is unsupported without direct experimental evidence.
- The potential utility of the core structure as a lead for further optimization is speculative and cannot be assessed from the abstract.